following a full submission:
pembrolizumab (Keytruda®) is accepted for use within NHSScotland.
Indication under review: As monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC) at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
In a phase III study, pembrolizumab significantly improved investigator-assessed disease-free survival (DFS) when compared with placebo.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results
Download detailed advice790KB (PDF)
Medicine details
- Medicine name:
- pembrolizumab (Keytruda)
- SMC ID:
- SMC2479
- Indication:
Pembrolizumab monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 October 2022